STOCKWATCH: Waving goodbye to value as IPO Window closes?
This article was originally published in Scrip
Executive Summary
It must have been a tense board meeting. Starting at 9.00 p.m. UK time on Thursday 12 November, Oxford Immunotec's bankers, investors and management convened to push a small, non-US-domiciled diagnostics company through an opening in the Nasdaq initial public offering window. Had they not been desparate, they might have noticed that "small", "non-US-domiciled" and "diagnostics" are not usually key attributes of successful Nasdaq IPOs. Neither, usually, is "late".